01 The Real Challenges of Viral Diseases

In the face of viral diseases with no vaccines, no specific drugs, or limited conventional treatment options, modern medicine has long faced significant challenges. Especially during outbreaks of emerging infectious diseases, the ability to directly inhibit viral replication under safe conditions and demonstrate continuous improvement in real-world cases is key to evaluating the value of an antiviral approach.

In the era without vaccines or specific drugs, directly inhibiting viral replication is particularly crucial.

02 Closed Loop of Experimental Results and Clinical Cases

We have observed a continuous chain of evidence from experiments to the real world: In in vitro experiments of wild-type SARS-CoV-2 completed under BSL-3 conditions, samples still showed clear inhibitory signals after high-fold dilution; in the SIV infection model in non-human primates, the viral load in the treatment group did not continue to rise with the natural course of the disease; among pregnant women, children, general adults, and severely infected patients, multiple types of case closed loops were formed, including nucleic acid positivity, intervention, continuous improvement, and subsequent negative conversion.

Even after high-fold dilution, it still directly inhibits viral replication, presenting a highly impactful research signal.

03 Practical Significance and Future Prospects

The importance of this series of results lies in the fact that it does not remain a single experimental phenomenon but is forming a three-in-one antiviral research structure of "in vitro experiments—animal validation—clinical cases." It suggests that a new antiviral pathway based on traditional Chinese medicine science and herbal nutrition is gradually moving from traditional experience to modern data validation.

From experiments to case closed loops, a new antiviral pathway is being gradually opened.